{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVIG&page=7",
    "query": {
      "intervention": "IVIG",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 291,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVIG&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVIG&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T12:27:03.740Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02556775",
      "title": "Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Exposure During Pregnancy"
      ],
      "interventions": [
        {
          "name": "A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 16,
      "start_date": "2015-12-04",
      "completion_date": "2019-12-17",
      "has_results": true,
      "last_update_posted_date": "2021-04-28",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02556775"
    },
    {
      "nct_id": "NCT05404919",
      "title": "Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Transplant",
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-09-06",
      "completion_date": "2024-08-01",
      "has_results": false,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05404919"
    },
    {
      "nct_id": "NCT04208828",
      "title": "IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastrointestinal Motility Disorder",
        "Gastroparesis",
        "Neuropathy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "12 Years to 90 Years"
      },
      "enrollment_count": 400,
      "start_date": "2020-01-02",
      "completion_date": "2028-01-02",
      "has_results": false,
      "last_update_posted_date": "2025-08-01",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04208828"
    },
    {
      "nct_id": "NCT07540221",
      "title": "A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)"
      ],
      "interventions": [
        {
          "name": "Gamunex-C",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Xembify",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-04-02",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 9,
      "location_summary": "Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07540221"
    },
    {
      "nct_id": "NCT02269163",
      "title": "Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prometic's Immune Globulin Intravenous 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Prometic Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "2 Years to 80 Years"
      },
      "enrollment_count": 82,
      "start_date": "2016-01-26",
      "completion_date": "2019-01-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 13,
      "location_summary": "Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269163"
    },
    {
      "nct_id": "NCT06818656",
      "title": "The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "PANDAS",
        "PANS",
        "PANS Pediatric Acute-Onset Neuropsychiatric Syndrome",
        "Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)",
        "Pediatric Acute-Onset Neuropsychiatric Syndrome",
        "Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Brain Inflammation Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "2 Years to 89 Years"
      },
      "enrollment_count": 65,
      "start_date": "2025-03-01",
      "completion_date": "2025-06-19",
      "has_results": false,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 1,
      "location_summary": "Delafield, Wisconsin",
      "locations": [
        {
          "city": "Delafield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06818656"
    },
    {
      "nct_id": "NCT00782106",
      "title": "Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases (PID)"
      ],
      "interventions": [
        {
          "name": "Recombinant human hyaluronidase + immune globulin intravenous",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2006-12-04",
      "completion_date": "2007-11-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 3,
      "location_summary": "Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782106"
    },
    {
      "nct_id": "NCT04153422",
      "title": "IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Fiber Neuropathy",
        "Autoimmune Small Fiber Neuropathy",
        "Inflammatory Polyneuropathy",
        "Immune-Mediated Neuropathy"
      ],
      "interventions": [
        {
          "name": "Panzyga IVIG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-12-15",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 1,
      "location_summary": "Glenview, Illinois",
      "locations": [
        {
          "city": "Glenview",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04153422"
    },
    {
      "nct_id": "NCT02465359",
      "title": "Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Subcutaneous (Human)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2014-09",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465359"
    },
    {
      "nct_id": "NCT00845650",
      "title": "Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "AIGIV 3.5 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gamunex 90 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AIGIV 7.0 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gamunex 180 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AIGIV 14.0 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gamunex 360 mg/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 129,
      "start_date": "2009-02",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-19T12:27:03.740Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845650"
    }
  ]
}